Moderna COVID-19 vaccine (redirect from MRNA-1273)
mRNA-1273/background/2021.1. Scholia has a profile for mRNA-1273 vaccine (Q87775025). Wikimedia Commons has media related to MRNA-1273. Wikinews...
165 KB (13,017 words) - 10:25, 1 June 2024
An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules...
77 KB (7,879 words) - 19:53, 31 May 2024
Solid lipid nanoparticle (redirect from MRNA-lipid nanoparticle)
a complex of plasmid or linear DNA and lipids Targeted drug delivery mRNA-1273, from Moderna, uses LNPs BNT162b2, from BioNTech/Pfizer, uses LNPs Saupe...
23 KB (2,629 words) - 15:37, 19 March 2024
the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States. In 2022...
25 KB (1,990 words) - 12:45, 11 June 2024
COVID-19 vaccine (redirect from MRNA-lipid nanoparticle COVID-19 vaccines)
mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 24 July 2021. "Background document on the mRNA-1273 vaccine...
192 KB (22,044 words) - 01:24, 5 June 2024
PMID 30785039. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19), clinicaltrials.gov...
7 KB (628 words) - 18:17, 27 March 2024
Nucleoside-modified messenger RNA (redirect from Nucleoside-modified mRNA)
developed by the cooperation of BioNTech/Pfizer (BNT162b2), and by Moderna (mRNA-1273). The zorecimeran vaccine developed by Curevac, however, uses unmodified...
24 KB (2,503 words) - 11:29, 22 February 2024
which biotechnology company Moderna used as the basis for the vaccine mRNA-1273, the first COVID-19 vaccine candidate to enter phase I clinical trials...
30 KB (2,822 words) - 17:59, 15 February 2024
; Hernán, Miguel A. (2022-07-01). "Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans". JAMA Internal Medicine...
16 KB (1,510 words) - 19:37, 11 April 2024
Pfizer–BioNTech COVID‑19 vaccine. A week later, they granted an EUA for mRNA-1273 (active ingredient elasomeran), the Moderna vaccine. On 31 March 2021...
122 KB (11,028 words) - 02:32, 27 January 2024